|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-32.48/-0.13
|
企業價值
15.69M
|
資產負債 |
每股賬面淨值
0.30
|
現金流量 |
現金流量率
--
|
損益表 |
收益
5.00K
|
每股收益
0.18
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/06/13 16:37 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. |